Prophase Labs Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 1.59, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the Prophase Labs Inc in Jun 30 2026 quarter, has decreased to 230 days, compared to 716 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 566 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 3700 to 3775.

What is Receivable Turnover Ratio?
What is Prophase Labs Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PRPH Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	-92.32 %	-92.36 %	-92.34 %	-89.62 %	-39.02 %
Y / Y Revenue Change	-18.93 %	-66.6 %	-	-69.07 %	-18.18 %
Receivable Turnover Ratio (TTM)	1.59	0.51	0.38	0.07	0.13
PRPH's Total Ranking	# 3775	# 3700	# 0	# 2915	# 2646
Accounts Receivable average collection period days	229	713	949	5421	2771
Seq. Receivable Change	0 %	0.46 %	-53.23 %	-83.65 %	-0.58 %
Seq. Revenue Change	111.51 %	-39.03 %	-10.6 %	-29.67 %	-12.86 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 199
Healthcare Sector	# 567
Overall Market	# 3775

Receivable Turnover Ratio Statistics
High	Average	Low
1.67	0.85	0.02
(Dec 31 2016)		(Sep 30 2025)

PRPH Company Profile • Back to PRPH Efficiency Comparisons • Compare PRPH Receivables Turnover Ratio to its Competitors

Financial Statements
Prophase Labs Inc 's Accounts Receivable	$ 2 Millions	Visit PRPH's Balance sheet
Prophase Labs Inc 's Sales TTM	$ 3 Millions	Visit PRPH's Income Statement
Sources of PRPH's Revenues		Visit PRPH's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
PRPH's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
PRPH's Growth Rates	PRPH's Roa	PRPH's Inventory Turnover Ratio	PRPH's Dividend Comparisons
PRPH's Profitability Ratios	PRPH's Roi	PRPH's Asset Turnover Ratio	PRPH's Dividend Growth
PRPH's Valuation Ratios	PRPH's Roe	PRPH's Financial Strength Ratios	PRPH's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Surgery Partners Inc	5.61	$ 3,366.300 Millions	$ 600.375 Millions
Bioxcel Therapeutics Inc	5.59	$ 0.742 Millions	$ 0.133 Millions
Integer Holdings Corporation	5.57	$ 1,842.621 Millions	$ 330.687 Millions
Intelligent Bio Solutions Inc	5.51	$ 4.215 Millions	$ 0.765 Millions
Johnson and Johnson	5.47	$ 97,929.000 Millions	$ 17,889.000 Millions
Merck and Co Inc	5.47	$ 66,569.000 Millions	$ 12,167.250 Millions
Quanterix Corporation	5.45	$ 152.716 Millions	$ 28.030 Millions
Brightspring Health Services Inc	5.45	$ 5,877.918 Millions	$ 1,079.324 Millions
Charles River Laboratories International inc	5.44	$ 3,998.987 Millions	$ 734.654 Millions
Rigel Pharmaceuticals Inc	5.43	$ 276.785 Millions	$ 50.994 Millions
Blue Water Vaccines Inc	5.42	$ 0.646 Millions	$ 0.119 Millions
Igc Pharma Inc	5.36	$ 1.101 Millions	$ 0.206 Millions
Strata Critical Medical Inc	5.27	$ 211.642 Millions	$ 40.126 Millions
Karyopharm Therapeutics Inc	5.27	$ 146.621 Millions	$ 27.821 Millions
Elutia Inc	5.16	$ 11.353 Millions	$ 2.198 Millions
West Pharmaceutical Services Inc	5.12	$ 3,326.900 Millions	$ 649.250 Millions
Repligen Corp	5.09	$ 785.101 Millions	$ 154.205 Millions
Progyny Inc	5.09	$ 1,311.298 Millions	$ 257.570 Millions
Pfizer Inc	4.98	$ 63,696.000 Millions	$ 12,802.250 Millions
Stereotaxis Inc	4.98	$ 29.892 Millions	$ 6.008 Millions
Invivyd Inc	4.96	$ 58.365 Millions	$ 11.776 Millions
Agilent Technologies inc	4.96	$ 7,372.000 Millions	$ 1,487.500 Millions
Plus Therapeutics Inc	4.90	$ 4.203 Millions	$ 0.858 Millions
Abeona Therapeutics Inc	4.83	$ 30.093 Millions	$ 6.232 Millions
Ligand Pharmaceuticals Incorporated	4.77	$ 290.542 Millions	$ 60.966 Millions
Personalis Inc	4.75	$ 69.669 Millions	$ 14.676 Millions
Bausch and Lomb Corp	4.65	$ 5,324.000 Millions	$ 1,144.000 Millions
Davita Inc	4.64	$ 14,009.646 Millions	$ 3,018.719 Millions
Orasure Technologies Inc	4.62	$ 111.978 Millions	$ 24.227 Millions
Kura Oncology Inc	4.60	$ 77.225 Millions	$ 16.784 Millions

Date modified: 2026-08-31T13:29:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.